Market Reports Center

In Situ Hybridization: Market Shares, Strategies, and Forecasts, Worldwide, 2018 to 2024


Report Details

In Situ Hybridization: Market Shares, Strategies, and Forecasts, Worldwide, 2018 to 2024

SKU WGJMAR151802
Category Life Sciences
Publisher Wintergreen Research
Pages 242
Published Mar-18
Request Discount Pay by Wire/Invoice

Description

The global market for In Situ Hybridization (ISH) at $4.3 billion in 2017 is anticipated to reach $7.8 billion by 2024. Worldwide markets are poised to achieve continuing growth as In Situ Hybridization is used in diagnostic situations to analyze single cells inside tissue. Managing single cell diagnostics in real time, encouraging collaborative business efforts. Lowering transaction management costs is a key benefit.

In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand (i.e., probe) to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small enough (e.g., plant seeds, Drosophila embryos), in the entire tissue (whole mount ISH), in cells, and in circulating tumor cells (CTCs).
Advances in RNA in situ hybridization transform molecular detection with morphological context enabling new applications. Scientists use RNA ISH to extract data dimensions.
Immunohistochemistry (IHC) and RNA in situ Hybridization are widely used technologies sharing the unique capacity to analyze a marker at the single cell level while preserving the morphological context. In different situations, IHC and ISH are used in conjunction to validate data or provide complementary information.

In situ hybridization (ISH) is a powerful technique for localizing specific nucleic acid targets within fixed tissues and cells, allowing users to obtain temporal and spatial information about gene expression and genetic loci. While the basic workflow of ISH is similar to that of blot hybridizations—the nucleic acid probe is synthesized, labeled, purified, and annealed with the specific target—the difference is the greater amount of information gained by visualizing the results within the tissue.

The global market for In Situ Hybridization (ISH) at $4.3 billion in 2017 is anticipated to reach $7.8 billion by 2024 2017. CAGR of 7.8% in the next five years (2017 to 2024). Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are expected to drive the growth of the market in the coming years.

Key Topics
In Situ Hybridization
Molecular Diagnostics
Cervical Cancer Stain
Fish Steps Reduction
Fluorescence In Situ Hybridization (FISH)
In Situ Hybridization (ISH)
FISH Probe Kit
Cancer
Chromosonal Abnormalities
Infectious Diseases
Inflammatory Diseases
Fluorescence In Situ Hybridization (FISH)
Chromogenic In Situ Hybridization (CISH)
Human Genetic Tests
Microbial Tests
In Vitro Diagnostics
System for the Analysis of Solid Tumors
Hybridization Technique
Detection of Long Non-
Coding DNA
Coding RNA


News/Press Release

Table of Content

Table of Contents 3
US In situ Hybridization Executive Summary 15
In Situ Hybridization (ISH) 15
1. United States In Situ Hybridization ISH Market
Definition and Market Dynamics 16
1.1 US In situ Hybridization Market Overview 16
1.1.1 Antibody Challenges and Validation 16
1.2 Scope of In situ Hybridization in Inflammation 17
1.2.1 RNAscope® Applications 17
2. In-Situ Hybridization Market Shares and Market
Forecasts 20
2.1 In-Situ Hybridization Market Driving Forces 20
2.1.1 Identification of Cytokines and their Cellular Origins 21
2.1.2 Detection of Long Non-Coding RNA (lncRNA) in Inflammatory Diseases
2.1.3 Role of Inflammatory Pathways During Carcinogenesis 22
2.1.4 Therapeutic Potential Of Secreted Proteins In Inflammatory Diseases 22
2.1.5 Dual ISH-IHC Detect Cytokines During Inflammatory Responses 22
2.2 In Situ Hybridization Market Shares 24
2.2.1 Roche 25
2.2.2 Abbott Molecular 25
2.2.3 Advanced Cell Diagnostics 25
2.2.4 PerkinElmer In Situ Hybridization Market Driving Forces 26
2.2.5 In Situ Hybridization Market Shares, Unit Shipments and Kit Shipments
27
2.3 In Situ Hybridization Market Forecasts 29
2.3.5 In Situ Hybridization Market Segments, Units and Kits, Dollars and
Percent, US, 29
2.4 In situ Hybridization Market Segments 31
2.4.1 In Situ Hybridization Market Shares, Dollars, Worldwide, 2012 to 2017
32
2.4.2 Fluorescence (FISH) and Chromogenic (CISH) Detection 33
2.4.3 ISH Applications 36
2.4.4 Multiplex Fluorescence In Situ Hybridization (FISH) 36
2.4.5 Fluorescence In Situ Hybridization (FISH) 37
2.4.6 Cancer Drug Market 40
2.4.7 Chronic Lymphocytic Leukemia (CLL) 40
2.4.8 In-Situ Hybridization Cancer Diagnosis, Cytology, Infectious Disease
Molecular Diagnostic 42
2.1.6 In Situ Hybridization Market Segments, Diagnostic Laboratories,
Academic & Research Institutes, Contract Research Organizations, and
Pharmaceutical & Biotechnology Companies 47
2.5 In-Situ Hybridization Pricing 54
2.5.1 miRCURY LNA miRNA Detection Probes 54
2.5.2 Price and Availability 58
2.6 In-Situ Hybridization Geographical Analysis 61
3 In-Situ Hybridization Research and Technology 68
3.1 Hybridization Technique 68
4 In-Situ Hybridization Company Profiles 69
4.1 Abbott Laboratories 69
4.1.1 Abbott Laboratories Market Categorization 69
4.1.2 In Situ Hybridization Product Category, Application and Specification 70
4.1.3 Abbott Laboratories Vysis Chronic Lymphocytic Leukemia (CLL) FISH
Probe Kit (IVD) 71
4.1.4 Vysis CLL FISH Probe Kit Contents 72
4.1.5 Acupath Laboratories Test For Detecting Bladder Cancer Uses Probes
from Abbott Molecular 74
4.1.6 Abbott Laboratories Barrett’s Esophagus FISH 75
4.1.7 Abbott Molecular Vysis CLL FISH Probe Kit | 77
4.1.8 Abbott Laboratories Revenue 77
4.1.9 Abbott Laboratories ThermoBrite System 81
4.1.10 Abbott Laboratories User Programmable Settings 82
4.1.11 Abbott Laboratories Vysis FISH Chromosome Search 83
4.1.12 Abbott Laboratories Molecular Diagnostics 84
4.1.13 Abbott Diagnostic Products 85
4.2 Acupath Laboratories
4.2.1 Acupath Laboratories Barrett’s Esophagus FISH 88
4.3 Agilent Technologies 88
4.3.1 Agilent CGH & CGH+SNP Microarrays 91
4.3.2 Agilent Technologies Revenue 91
4.3.3 Agilent Diagnostics and Genomics 93
4.4 Bio-Techne / ACD 96
4.4.1 Bio-Techne ACD RNAscope Widely Used In-Situ Hybridization
Technique 97
4.4.2 Bio-Techne Revenue 98
4.4.3 Biotechne US Regional Analysis 101
4.4.4 Advanced Cell Diagnostics 102
4.5 F. Hoffmann-La Roche AG 102
4.5.1 Roche Gene Amplification by Fluorescence In Situ Hybridization 104
4.5.2 Roche Automated RNA isolation 105
4.5.3 Roche Fluorescence In Situ Hybridization (FISH) 105
4.5.4 Roche Agreement with Merck Millipore Sigma 106
4.5.5 Roche Immuno Diagnostics 108
4.5.6 F. Hoffmann-La Roche AG Revenue 109
4.5.7 Roche Buys Flatiron Health Leader In Oncology-Specific Electronic
Health Record (EHR) Software 114
4.6 Danaher / Leica Biosystems Nussloch GmbH 115
4.6.1 Leica Biosystems Nussloch GmbH BOND IHC/ISH Instruments 116
4.6.2 Leica Biosystems Nussloch GmbH Revenue 122
4.6.3 Danaher Geographical Revenue 124
4.7 Thermo Fisher Scientific 125
4.7.1 Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH) 125
4.7.2 Chromogenic In Situ Hybridization (CISH) 128
4.7.3 Thermo Fisher Scientific Revenue 133
4.8 Merck KGaA 134
4.9 PerkinElmer 135
4.9.1 PerkinElmer Stain 144
4.9.2 Perkin Elmer Revenue 146
4.10 Qiagen / Exiqon A/S 150
4.10.1 Qiagen’s GeneReader NGS System 153
4.10.2 Polygenetic Mutations Drive Cancer 153
4.10.3 Qiagen Revenue 154
4.11 BioGenex Laboratories 155
4.11.1 BioGenex Fully-Automated Molecular Pathology Workstation 156
4.11.2 BioGenex Boosts Genome Research and Diagnostics - BioGenex US 159
4.11.3 BioGenex Antibodies for Cancer Diagnosis 161
4.11.4 BioGenex PMS2 161
CK5 162
4.11.5 eFISHiency System for the Analysis of Solid Tumors - BioGenex US 163
4.12 Bio SB 165
4.12.1 Bio SB Zytovision Molecular Diagnostics 165
4.13 Bio-Techne / Advanced Cell Diagnostics (ACD) 167
5 Summary and Conclusions 172
5.1 Analyze A Marker At The Single Cell Level 172
5.2 Advances in RNA In Situ Hybridization 172
6 Appendix A: List Of Nucleic Acid-Based Tests 173
6.1 List: Nucleic Acid-Based Tests Approved by US Center for Devices and
Radiological Health 173
6.1.1 List of Human Genetic Tests 174
6.1.2 List of Microbial Tests 191
6.2 In Vitro Diagnostics 233

List of Figures

Abstract: In Situ Hybridization Reagents Make It Possible To Visualize Expression
Of Virtually Any Gene In Individual Cells While Retaining Valuable Tissue
Morphology Information 1
Figure 1. In Situ Hybridization Market Shares, Dollars, US, 2016 and 2017 24
Figure 2. In Situ Hybridization Market Driving Forces 26
Figure 3. In Situ Hybridization Market Shares, Unit Shipments and Kit Shipments,
Units and Dollars, US, 2017 27
Figure 4. In Situ Hybridization Market Shares, $ per Unit and $ per Kit, Dollars and
Percent, US, 2017 28
Figure 5. In Situ Hybridization Market Segments, Unit Shipments and Kit
Shipments, Units and Dollars, US, 2017 29
Figure 6. In Situ Hybridization Market Segments, $ per Unit and $ per Kit, Dollars
and Percent, US, 2017 30
Figure 7. In Situ Hybridization Market Shares, Dollars, Worldwide, 2012 to 2017
32
Figure 8. In Situ Hybridization Market Segments, Fluorescence In Situ
Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH), US, 2012 to
2017 33
Figure 9. In Situ Hybridization Market Segments, Fluorescence In Situ
Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH), US, 2017 to
2024 34
Figure 10. Thermo Fisher Scientific Characteristics of In Situ Hybridization
Methods 35
Figure 11. Diagnostics Growth 42
Figure 12. In Situ Hybridization Market Segments, Cancer, Chromosonal
Abnormalities, Infectious Diseases, Dollars, US, 2012 to 2017 43
Figure 13. In Situ Hybridization Market Segments, Cancer, Chromosonal
Abnormalities, Infectious Diseases, Dollars, US, 2017 to 2024 44
Figure 14. In Situ Hybridization Market Segments, Cancer, Chromosonal
Abnormalities, Infectious Diseases, Percent, US, 2017 to 2024 45
Figure 15. In Situ Hybridization Market Segments, Cancer, Chromosonal
Abnormalities, Infectious Diseases, Percent, US, 2012 to 2017 45
Figure 16. In Situ Hybridization Market Segments, Diagnostic Laboratories,
Academic & Research Institutes, Contract Research Organizations, and
Pharmaceutical & Biotechnology Companies, Dollars, US, 2012 to 2017 47
Figure 17. In Situ Hybridization Market Segments, Diagnostic Laboratories,
Academic & Research Institutes, Contract Research Organizations, and
Pharmaceutical & Biotechnology Companies, Dollars, US, 2017 to 2024 48
Figure 18. In Situ Hybridization Market Segments, Diagnostic Laboratories,
Academic & Research Institutes, Contract Research Organizations, and
Pharmaceutical & Biotechnology Companies, Percent, US, 2012 to 2017 49
Figure 19. In Situ Hybridization Market Segments, Diagnostic Laboratories,
Academic & Research Institutes, Contract Research Organizations, and
Pharmaceutical & Biotechnology Companies, Percent, US, 2017 to 2024 50
Figure 20. 575 Million People with Autoimmune Disease 51
Figure 21. PerkinElmer Assays for Autoimmune Disease 52
Figure 22. PerkinElmer Diagnostics 53
Figure 23. PerkinElmer In Situ Hybridization 57
Figure 24. In Situ Hybridization Regional Analysis, US: West, Rocky Mountain,
Southwest, Midwest, South, Middle Atlantic, New York and New England,
Percent, 2012 – 2017 63
Figure 25. In Situ Hybridization Regional Analysis, US: West, Rocky Mountain,
Southwest, Midwest, South, Middle Atlantic, New York and New England,
Percent, 2017 - 2024 65
Figure 26. Abbott Laboratories Vysis CLL FISH Probe Kit Probe Info 71
Figure 27. Abbott Laboratories Vysis CLL FISH Probe Kit Contents 72
Figure 28. Abbott Laboratories Vysis CLL FISH Probe Kit includes LSI 72
Figure 29. Abbott Vysis CLL FISH Probe Kit 73
Figure 30. Abbott Laboratories Segment Sales, 2017 78
Figure 31. Abbott Segment Sales 2015-2017 79
Figure 32. Abbott Geographical Revenue 80
Figure 33. Abbott Laboratories ThermoBrite System 81
Figure 34. Abbott Laboratories ThermoBrite System Functions 82
Figure 35. Abbott Laboratories Molecular Testing 84
Figure 36. Abbott Diagnostic Product Target Markets 85
Figure 37. Abbott Diagnostic Principal Products 86
Figure 38. In Situ Hybridization Detection System: Agilent Product Area: Standard
Nucleic Acid Detection System 88
Figure 39. PNA ISH Detection Kit Product Area: PNA Probes & Detection System
90
Figure 40. Roche RNA Isolation Kit 105
Figure 41. Merck MilliporeSigma and Sigma-Aldrich and Roche Offerings 107
Figure 42. Key points of the Roche Merc agreement include: 107
Figure 43. Roche Immuno Diagnostics DISCOVERY XT 108
Figure 44. Roche DISCOVERY XT Research Instrument Functions 109
Figure 45. F. Hoffmann-La Roche AG Sales 110
Figure 46. Roche by the Metrics 112
Figure 47. F. Hoffmann-La Roche AG Pharmaceutical Sales 113
Figure 48. Danaher Brands 116
Figure 49. Leica Biosystems Bond III Technical Specifications 117
Figure 50. Leica Biosystems Nussloch GmbH BOND IHC/ISH Instruments 118
Figure 51. Leica SCN400 Slide Scanner Features 119
Figure 52. Leica BOND Ready-To-Use Antibodies (No Mixing, Titration Or Dilution)
120
Figure 53. Leica Biosystems 121
Figure 54. Danaher Segment Revenue 123
Figure 29. Abbott Vysis CLL FISH Probe Kit 73
Figure 30. Abbott Laboratories Segment Sales, 2017 78
Figure 31. Abbott Segment Sales 2015-2017 79
Figure 32. Abbott Geographical Revenue 80
Figure 33. Abbott Laboratories ThermoBrite System 81
Figure 34. Abbott Laboratories ThermoBrite System Functions 82
Figure 35. Abbott Laboratories Molecular Testing 84
Figure 36. Abbott Diagnostic Product Target Markets 85
Figure 37. Abbott Diagnostic Principal Products 86
Figure 38. In Situ Hybridization Detection System: Agilent Product Area: Standard
Nucleic Acid Detection System 88
Figure 39. PNA ISH Detection Kit Product Area: PNA Probes & Detection System
90
Figure 40. Roche RNA Isolation Kit 105
Figure 41. Merck MilliporeSigma and Sigma-Aldrich and Roche Offerings 107
Figure 42. Key points of the Roche Merc agreement include: 107
Figure 43. Roche Immuno Diagnostics DISCOVERY XT 108
Figure 44. Roche DISCOVERY XT Research Instrument Functions 109
Figure 45. F. Hoffmann-La Roche AG Sales 110
Figure 46. Roche by the Metrics 112
Figure 47. F. Hoffmann-La Roche AG Pharmaceutical Sales 113
Figure 48. Danaher Brands 116
Figure 49. Leica Biosystems Bond III Technical Specifications 117
Figure 50. Leica Biosystems Nussloch GmbH BOND IHC/ISH Instruments 118
Figure 51. Leica SCN400 Slide Scanner Features 119
Figure 52. Leica BOND Ready-To-Use Antibodies (No Mixing, Titration Or Dilution)
120
Figure 53. Leica Biosystems 121
Figure 54. Danaher Segment Revenue 123
Figure 78. Figure: Colon Carcinoma stained with PMS2 (clone EP51),Staining in
FFPE tisues, using DAB chromogen and BioGenex Polymer-HRP Detection System.
162
Figure 79. BioGenex Cervical Cancer Stained with Anti-Human CK-5 (clone
EP24),Staining in FFPE Tissues, Using DAB Chromogen and Polymer-HRP Detection
System 163
Figure 80. BioGenex Fish Steps Reduction 164
Figure 81. BioGenex eFISHiency System Reduces Hands-On Processing Time To 30
Minutes 165
Figure 82. Bio SB Zytovision Molecular Diagnostics 165
Figure 83. Bio-Techne / ACD 170

Companies Profiled

Companies Profiled
Leica Biosystems
Nussloch GmbH
Thermo Fisher Scientific
F. Hoffmann-La Roche AG
Abbott Laboratories
Agilent Technologies
PerkinElmer
Qiagen / Exiqon A/S
Merck KGaA
BioGenex Laboratories
BioTechne / Advanced Cell Diagnostics (ACD)

Market Reports Center © Copyright 2018 All rights reserved.

wire transfer
HDFC
ssl